2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million. “We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team,” said Derek Maetzold, president and chief executive officer of Castle Biosciences (CSTL).
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences price target raised to $43 from $30 at Guggenheim
- Castle Biosciences price target raised to $50 from $37 at Canaccord
- Castle Biosciences reports inducement grants under Nasdaq listing rule
- Castle Biosciences announces new data on DecisionDx-UM, PRAME
- Castle Biosciences price target raised to $50 from $38 at BTIG